CTIT
Conditions
Interventions
Ropristine in combination with or without small molecule thrombopoietin receptor agonist group:None
Sponsors
Sheyang County People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. The patient signs an informed consent form, voluntarily joins this study, and has the willingness and ability to cooperate with data collection in this study; 2. Diagnosed with malignant tumor and currently undergoing anti-tumor treatments such as chemotherapy, radiotherapy, immunotherapy, and targeted therapy, with PLT<75 × 10^9/L during treatment; 3.Romiplostim was prescribed for the first time at the time of inclusion (Romiplostim was prescribed at the discretion of the supervising physician and was not affected by this study.
Exclusion criteria
Exclusion criteria: 1. The patient is currently undergoing or planned to be enrolled in a clinical intervention study; 2. Unable to understand the nature of the research or without obtaining informed consent; 3. Researchers determine other situations that are not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients who respond within 7 days of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Platelet count changes during treatment;Proportion of subjects whose PLT recovered to =75×109/L within 14 days of treatment;The time of platelet recovery to =75×109/L and 100×109/L during treatment;Adverse reaction; | — |
Countries
China
Contacts
Public ContactLei Xing
Sheyang County People's Hospital
Outcome results
None listed